Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Pharmaceutical composition of forskolin/iforeskolin and pentacyclic triterpenes and application thereof

A technology of pentacyclic triterpenoids and compositions, applied in the direction of drug combinations, medical preparations containing active ingredients, pharmaceutical formulas, etc., to achieve the effects of orderly arrangement of liver cells, improvement of liver function, and reduction of fat accumulation

Active Publication Date: 2022-06-21
CHINA PHARM UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0017] At present, there is no report on forskolin / iforeskolin combined with pentacyclic triterpenoids for the prevention and treatment of metabolic diseases, fibrosis diseases and liver diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition of forskolin/iforeskolin and pentacyclic triterpenes and application thereof
  • Pharmaceutical composition of forskolin/iforeskolin and pentacyclic triterpenes and application thereof
  • Pharmaceutical composition of forskolin/iforeskolin and pentacyclic triterpenes and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Example 1: The therapeutic effect of the pharmaceutical composition of the present invention on high-fat diet-induced obesity model and fatty liver model.

[0045] To compare the therapeutic effects of forskolin / isoforskolin combined with pentacyclic triterpenoids and alone on high-fat diet-induced obesity and fatty liver models to verify the synergistic treatment of the composition of the present invention Effect.

[0046] 1. Establishment of non-alcoholic fatty liver model mice

[0047] After 160 SPF grade 8-9 weeks old male C57 mice were adaptively reared for one week, 140 mice with uniform body weight and obesity were selected and divided into 14 groups on average, 10 mice in each group, which were model group (M group) , forskolin group (F group), isforskolin group (IF group), asiatic acid group (AA group), madecassoside group (AS group), oleanolic acid group (OA group) , betulinic acid group (BA group), forskolin+asiatic acid combination group (F+AA group), fors...

Embodiment 2

[0072] Embodiment 2 pharmaceutical composition of the present invention to CCl 4 Therapeutic effects in an induced model of chronic liver fibrosis compared with forskolin combined with pentacyclic triterpenoids and alone on CCl 4 The therapeutic effect of the induced chronic liver fibrosis model mice to verify the synergistic therapeutic effect of the composition of the present invention.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a pharmaceutical composition, which comprises two components, the first component is selected from forskolin, isofaskolin or pharmaceutically acceptable salts thereof; the second component is selected from five Cyclic triterpenoids or pharmaceutically acceptable salts thereof. The pharmaceutical composition of the present invention uses forskolin / iforeskolin and pentacyclic triterpenoids in combination, compared with using the two components alone, it can prevent and treat metabolic, fibrosis, and liver diseases It has a significant synergistic effect, so it has broad medicinal prospects in the treatment, prevention, and improvement of diseases such as obesity, non-alcoholic fatty liver, liver injury, and liver fibrosis.

Description

technical field [0001] The invention belongs to the field of medicine, and relates to a pharmaceutical composition comprising forskolin / isoforskolin and pentacyclic triterpenoids and a medicine for preventing, improving or treating metabolic diseases, fibrotic diseases and liver diseases. use in. Background technique [0002] With the improvement of economic level, people's diet structure has undergone great changes, the intake of lipids has increased, and the number of obese people has gradually expanded. The World Health Organization (WHO) defines people with a body mass index (BMI) ≥ 25 as overweight. It leads to the occurrence of various metabolic diseases, such as diabetes, hypertension, hyperlipidemia, fatty liver and so on. Non-alcoholic fatty liver disease (NAFLD) is a type of disease characterized by lipid accumulation and degeneration in liver cells. The pathological section is mainly characterized by a significant increase in lipid droplets in liver cells, and in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/06A61K31/56A61K31/7024A61K31/352A61P3/10A61P3/06A61P3/04A61P9/00A61P9/10A61P13/12A61P11/00A61P17/00A61P1/16A61P35/00
CPCA61K45/06A61K31/352A61K31/56A61K31/7024A61P3/10A61P3/06A61P3/04A61P9/00A61P9/10A61P13/12A61P11/00A61P17/00A61P1/16A61P35/00A61K2300/00
Inventor 吴亮
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com